IL
IL3.F Integra LifeSciences Holdings Corporation
- Market cap
- EUR 995M
- P/E
- 85.3x
- P/B
- 0.46x
- ROE
- 0.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IL3.F undervalued?
Graham numberIL3.F trades 31.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Integra LifeSciences Holdings Corporation fundamental analysis
No fundamental analysis for Integra LifeSciences Holdings Corporation yet.
Integra LifeSciences Holdings Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitori…
Full company profileIntegra LifeSciences Holdings Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Integra LifeSciences Holdings Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 992M | 1.19B | 1.47B | 1.52B | 1.37B | 1.54B | 1.56B | 1.54B | 1.61B | 1.64B | 1.63B |
| Gross Profit | 643M | 753M | 901M | 953M | 851M | 945M | 970M | 885M | 882M | 832M | 862M |
| Operating Income | 115M | 44.8M | 111M | 159M | 151M | 197M | 239M | 112M | 28.4M | 18.0M | 66.2M |
| EBITDA | - | 135M | 233M | 224M | 281M | 282M | 277M | 256M | 193M | -325M | 269M |
| Net Income | 74.6M | 64.7M | 60.8M | 50.2M | 134M | 169M | 181M | 67.7M | -6.94M | -516M | 19.6M |
| EPS | - | 0.83 | 0.71 | 0.58 | 1.59 | 2.00 | 2.16 | 0.86 | -0.09 | -6.63 | 0.25 |
| Balance Sheet | |||||||||||
| Total Assets | 1.81B | 3.21B | 3.11B | 3.30B | 3.62B | 3.78B | 3.89B | 3.78B | 4.04B | 3.60B | 3.51B |
| Total Liabilities | 968M | 2.25B | 1.73B | 1.89B | 2.10B | 2.10B | 2.09B | 2.19B | 2.49B | 2.56B | 2.44B |
| Shareholders' Equity | 840M | 962M | 1.38B | 1.42B | 1.51B | 1.68B | 1.80B | 1.59B | 1.55B | 1.04B | 2.47B |
| Cash & Short-term Investments | 102M | 175M | 139M | 199M | 470M | 513M | 457M | 276M | 246M | 235M | 252M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 116M | 115M | 200M | 231M | 204M | 312M | 264M | 140M | 129M | 50.4M | 171M |
| Capital Expenditure | 47.3M | 43.5M | 77.7M | 69.5M | 38.9M | 48.0M | 42.3M | 66.9M | 114M | 95.6M | 49.9M |
| Free Cash Flow | - | 71.0M | 122M | 96.9M | 140M | 312M | 264M | 73.1M | 15.0M | -45.3M | 122M |
| Ratios | |||||||||||
| ROE | 8.9% | 6.7% | 4.4% | 3.5% | 8.8% | 10.0% | 10.0% | 4.3% | -0.4% | -49.5% | 0.8% |
| ROA | 4.1% | 2.0% | 2.0% | 1.5% | 3.7% | 4.5% | 4.6% | 1.8% | -0.2% | -14.3% | 0.6% |
| Net Profit Margin | 7.5% | 5.4% | 4.1% | 3.3% | 9.8% | 11.0% | 11.6% | 4.4% | -0.4% | -31.6% | 1.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Integra LifeSciences Holdings Corporation dividends
Integra LifeSciences Holdings Corporation has not paid dividends in the last 9 fiscal years.
Who owns Integra LifeSciences Holdings Corporation
- Insiders 14.38%
- Institutions 85.62%
- Public & others 0.00%
- Shares outstanding 77.8M
- Free float 58.6M
Integra LifeSciences Holdings Corporation company profile
- Company name
- Integra LifeSciences Holdings Corporation
- Ticker
- IL3.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 4,427
- Fiscal year end
- December
- Address
- 1100 Campus Road, Princeton, NJ, United States, 08540
- Phone
- 609 275 0500
- Website
- integralife.com
About Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Integra LifeSciences Holdings Corporation management
10- Dr. Stuart M. Essig Ph.D.CEO, President & Chairman · born 1962
- Ms. Lea Daniels KnightExecutive VP & CFO · born 1972
- Mr. Robert T. Davis Jr.Executive Vice President of Tissue Reconstruction and Distributed Technologies · born 1959
- Mr. Michael J. McBreenExecutive VP & Chief Commercial Officer · born 1966
- Mr. Harvinder Pal SinghExecutive VP & President of International Business · born 1966
- Mr. Jeffrey A. MosebrookSenior VP of Finance & Principal Accounting Officer · born 1976
- Mr. Teshtar ElaviaCorporate VP & Chief Technology Officer
- Christopher WardSenior Director of Investor Relations
- Mr. Michael D. HutchinsonExecutive VP, Chief Legal Officer & Secretary · born 1971
- Laurene IsipVice President of Global Corporate Communications & Public Relations